Treatment of ADHD With Atomoxetine in Children & Adolescents With ADHD & Comorbid Dyslexia

• Status: Completed
• Trial end date: 2011-02-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the effect of atomoxetine in treating Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms in children and adolescents with ADHD and comorbid reading disability (dyslexia)

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Atomoxetine Hydrochloride

Criteria

Inclusion Criteria:

• patients must meet Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) criteria for Attention-Deficit/Hyperactivity Disorder (ADHD)

• patients must achieve a score of 80 or more on the Full Scale Intelligence Quotient

• child or adolescent patients must be 10 to 16 years old

• must be able to communicate in English

• must be able to swallow capsules

• be reliable to keep appointments for clinic visits and all related tests

Exclusion Criteria:

• patients who weigh less than 25 Kg or greater than 70 Kg

• patients with a history of alcohol or drug abuse on a repeated basis within the past 3 months

• patients with documented history of autism, Asperger's syndrome or pervasive developmental disorder

• females who are pregnant or breastfeeding

• patients with a history of severe allergy to more than one class of medications

• patients with documented history of bipolar I or bipolar II disorder, or psychosis